O. Kalashnikova

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

E. Montserrat, K. Stamatopoulos, D. Lad, 2022, Journal of Hematology & Oncology.

Prediction of Treatment Efficacy in Relapsed Chronic Lymphocytic Leukemia

N. Mikhailova, E. Kondakova, M. Ivanova, 2021, Clinical oncohematology.

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

E. Montserrat, J. Delgado, K. Stamatopoulos, 2020, Leukemia.

Expression of CD68 and Fas Ligand in Colon Mucosa of Patients with Inflammatory Bowel Disease as Prognostic Markers of Cancerogenesis

O. Kalashnikova, V. Chasnyk, A. Kolobov, 2016 .

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

Поддубная Ирина Владимировна, Михайлова Наталья Борисовна, Медведева Надежда Вадимовна, 2020, Journal of Modern Oncology.

Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia

J. Hoheisel, T. Joos, S. Mastitsky, 2012, BMC Cancer.

Efficiency of first-line chemotherapy schemes at different stages of Hodgkin's lymphoma

K. Kaplanov, I. Matveeva, O. Kalashnikova, 2012 .

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

K. Stamatopoulos, D. Lad, T. Chatzikonstantinou, 2023, EClinicalMedicine.